AKT1 F55Y

CI-VAR-00001124Explore in graph →CIViC 4223

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
AKT1 F55Y	ARQ092 + CapivasertibSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID10766 Expression of AKT1 F55Y in MCF10a and Ba/F3 cells induced p-AKT in Ba/F3 and p-S6, and p-PRAS40 in both cell lines. Treatment with AKT inhibitors capivasertib and ARQ092 decreased cell vaibility and s… (full text at CIViC) PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.